Flik Therapeutics

Flik Therapeutics is a private U.S. healthcare/biotech company focused on developing FDA-regulated therapies for smoking cessation and nicotine de-addiction. The company is building a structured, multimodal cessation platform intended to improve quit rates versus currently available pharmacotherapies. Its lead investigational program, FLK-001, is described by the company as a novel therapy under FDA evaluation, with access currently limited to clinical trial participation. Publicly available non-dilutive funding records show the company received a 2024 NIH/NIDA SBIR Phase I award to support development of its core smoking-cessation pharmacotherapy platform. Overall, Flik appears to be an early-stage company centered on nicotine dependence, youth vaping, and related public health needs.